Tryp Therapeutics Inc. (CSE:TRYP)(OTCQB:TRYPF)(“Tryp”), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs through accelerated regulatory pathways, has announced that it will be presenting at H.C. Wainwright & Co.’s Psychedelics in Psychiatry and Beyond conference. The virtual event will be held on June 17, 2021. At the elite conference, Tryp chair and CEO Greg McKee will present an overview of the business including the company’s pipeline, which features its psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”), program for chronic pain and eating disorder indications. McKee’s prerecorded presentation will be available beginning 7 a.m. EDT on the ...
Read The Full Article On StreetSignals.com
Get the latest stock market news on StreetSignals . Follow public companies and get free stock research reports and stock market analysis data and stock tips.
All content provided by StreetSignals is subject to our Terms Of Use and Disclaimer .
For further details see:
PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) to Present at Upcoming H.C. Wainwright Psychedelics Conference